
Polyangiitis (severe active granulomatosis with polyangiitis or severe active microscopic polyangiitis) program in Pharmaceutical Benefits Scheme (PBS) 012-18051135

-   Background
-   Process
-   Resources

This procedure is under review. An Operational Message about this
content exists.

[Expand/Collapse all sections]Expand all

This document outlines information for PBS subsidies for rituximab for
patients with either severe active granulomatosis with polyangiitis or
severe active microscopic polyangiitis (SAPA). From 1 September 2022
rituximab will be listed as unrestricted benefit. Authority approval is
not required for prescribing the listed quantity and repeats. This page
has been decommissioned and is for information only.

Polyangiitis (severe active granulomatosis with polyangiitis or severe active microscopic polyangiitis) and listing dates

Severe active granulomatosis with polyangiitis (Wegeners granulomatosis)
or severe active microscopic polyangiitis (SAPA) are 2 rare conditions
that targets the blood vessels.

Listing dates are:

-   Rituximab - 1 January 2016

Enquiries

Transfer enquiries about prescription arrangements to the PBS authority
approval line.

The Resources page contains links to contact details, the PBS schedule
and the Services Australia website.

Related links

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

Process telephone Authority approval application

                                   

-   Services Australia ABN 90 794 605 008 
